Research & Technology

EmstoPA is an antibody-based reversal agent to treat bleeding caused by tPA, the “clot buster” used to treat stroke, pulmonary embolism and myocardial infarction. In the developed world, tPA is the standard care for treatment of ischemic stroke, but rates of subsequent intracranial hemorrhage (ICH) are 5-7%.

EmstoPA will address the fear of ICH, so that in turn more patients are treated with tPA, saving lives and improving recovery rates.

EmstoPA will be a first in class biotechnology product which addresses an area of high unmet medical need, for which there is no existing standard of care. It is currently the only specific antidote in development for tPA induced ICH. It will meet FDA / EMA criteria for innovation and accelerated drug approval as well as Orphan Drug status.